Chem. J. Chinese Universities ›› 2015, Vol. 36 ›› Issue (5): 919.doi: 10.7503/cjcu20140906

• Organic Chemistry • Previous Articles     Next Articles

Synthesis and Anti-tumor Activities of Novel Artemisone-piperazine-sulfonamide Derivatives

XU Jian1,3, WEI Mengxue1,2, LI Guoming3, LI Xueqiang1,2,*()   

  1. 1. School of Chemistry and Chemical Engineering
    2. Ningxia Development Center of Natural Products and Medication, Ningxia University, Yinchuan 750021
    3. Applied Technology Research Institute of Ningxia Baota Petrochemical Group, Yinchuan 750002
  • Received:2014-10-11 Online:2015-05-10 Published:2015-04-13
  • Contact: LI Xueqiang E-mail:lixq@nxu.edu.cn
  • Supported by:
    † Supported by the National Natural Science Foundation of China(Nos.21462032, 21062014), the Research Starting Funds for Imported Talents of Ningxia University, China(No.80020241) and the “211” Project in Ningxia University, China(No.ndzr09-1)

Abstract:

A series of artemisone derivatives was prepared from dihydroartemisinin through a seven-step conversion, which included the amination of dihydroartemisinin with thiomorpholine, the oxidation of thiomorpholine(2) with hydrogen peroxide, the alkylation of sulfone(3) with the silyl protected 4-iodobutan-1-ol, the desilylation of artemisone derivative(4), the conversion of alcohol(5) to iodide(6), the amination of iodide(6) with piperazine, and the sulfonylation of compound 7 with a wide arrange of sulfonyl chlorides to the desired artemisone derivatives(8). All the new compounds were identified by NMR spectra, IR and HRMS technology. The anti-tumor activities of artemisone derivatives against human hepatoma SMMC-7721 cell lines were evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide(MTT) method. It was found that these new artemisone-piperazine-sulfonamide derivatives could inhibit the proliferation of the liver cancer cell by inducing apoptosis, and the lowest IC50 value of the treatment for 72 h was 0.09 μmol/mL.

Key words: Artemisone, Piperazine, Sulfonamide, Anti-tumor activity

CLC Number: 

TrendMD: